The Board of Directors at Emcure Pharmaceuticals has approved the appointment of Mr. C S Muralidharan (DIN: 00014740) as an Additional Director (Non-Executive and Independent). This appointment will be effective from April 01, 2026, initially for a three-year term as an Independent Director, pending shareholder approval via postal ballot. Mr. Muralidharan brings 40 years of corporate experience, notably from Sun Pharmaceutical Industries Limited.
Outcome of Board Meeting on March 9, 2026
Emcure Pharmaceuticals announced key outcomes from its Board Meeting held on Monday, March 09, 2026. The primary approval concerns the addition of a new director to the Board, which will be ratified by members through a remote e-voting process conducted via Postal Ballot.
Appointment of Independent Director
The Board, acting on the recommendation of the Nomination and Remuneration Committee, approved the appointment of Mr. C S Muralidharan (DIN: 00014740).
- Designation: Additional Director (Non-Executive and Independent).
- Effective Date: April 01, 2026.
- Term: Approval for the first term of three (3) consecutive years as an Independent Director, effective April 01, 2026, contingent upon shareholder approval.
The disclosure confirms that Mr. Muralidharan is not debarred from holding a director’s office and he holds no relationship with any existing Director or Key Managerial Personnel of the Company.
Profile of Appointed Director
Mr. C. S. Muralidharan possesses extensive experience spanning 40 years across the hydro-carbon and pharmaceutical sectors. He has held senior leadership and board positions at various global entities, including Indian Oil Corporation Limited, Ranbaxy Group, Lupin Limited, and Matrix Laboratories Limited. In his most recent role, he served as the Group Chief Financial Officer at Sun Pharmaceutical Industries Limited, overseeing global finance, strategy, M&A, investor relations, governance, and compliance.
Academically, Mr. Muralidharan is a Cost & Management Accountant with a Master’s degree in Commerce. He also completed the Executive Program in General Management from the Booth School of Business, University of Chicago.
Ratification via Postal Ballot
To seek necessary approval for the appointment of Mr. Muralidharan as an Independent Director, the company will conduct a Postal Ballot utilizing remote e-voting facilities. The formal Notice of the Postal Ballot, detailing the cut-off date and e-voting period, will be communicated to members in due course.
The Board Meeting commenced at 12:15 p.m. (IST) and concluded at 12:40 p.m. (IST) on the date of the announcement.
Source: BSE
